Antifungal chemotherapy: Advances and perspectives

Swiss Medical Weekly

Volumn 132, Issue 23-24, 2002, Pages 303-311

  Groll, Andreas H ^a   Walsh, Thomas J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Antifungal agents; Mycoses; Prevention; Treatment

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; COLONY STIMULATING FACTOR 1; CYCLOSPORIN A; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4 ANTIBODY; ITRACONAZOLE; METHYLPREDNISOLONE; MICAFUNGIN; NIKKOMYCIN Z; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; EARLY DIAGNOSIS; HALLUCINATION; HUMAN; IMMUNOTHERAPY; NEPHROTOXICITY; NONHUMAN; SHORT SURVEY; VISUAL IMPAIRMENT;

EID: 0037098680     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (103)

1. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
2. Candidemia in cancer patients: A prospective, multicentre surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
3. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
4. Uncommon opportunistic fungi: New nosocomial threats
5. Clinical pharmacology of systemic antifungal agents
6. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
7. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses
8. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
9. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
10. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
11. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
12. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
13. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses
14. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
15. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
16. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
17. Antifungal pharmacodynamics. Concentration-effect relationships in vitro and in vivo
18. Amphoterincin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial
19. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
20. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infectons
21. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
22. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
23. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
24. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
25. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers
26. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis
27. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria
28. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematological malignancies, chronic granulomatous disease, or AIDS
29. Antifungal prophylaxis during neutropenia and immunodeficiency
30. A controlled trial oftrial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
31. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective randomized double blind study
32. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
33. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy
34. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
35. Prophylactic fluconazole in liver transplant patients. A randomized, double-blind, placebo-controlled trial
36. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study
37. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients
38. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
39. Fluconazole prophylaxis against fungal colonization and infection in preterm infants
40. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
41. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole
42. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
43. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
44. Empiric antifungal therapy in febrile granulocytopenic patients
45. Interventional antimicrobial therapy in febrile neutropenic patients - Paul Ehrlich Society for Chemotherapy (PEG) Study II
46. A randomized comparison of liposomal versus conventional amphotericin B for treatment ofpyrexia of unknown origin in neutropenic patients
47. Intravenous and oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy
48. A multicentre, randomized trial of fluconazole vs. amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
49. Voriconazole compared with liposomal amphotericin B for empirical intifungal therapy in patients with neutropenia and persistent fever
50. Diagnosis of invasive fungal infections: Advances in nonculture systems
51. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection
52. Hepatosplenic candidiasis: Wheels within wheels
53. Diagnosis and monitoring response to treatment of hepatosplenic candidiasis in patients with acute leukemia using magnetic resonance imaging
54. Paranasal sinusitis following allogeneic bone marrow transplant
55. Invasive pulmonary aspergillosis in acute leukemia: The contribution of CT to early diagnosis and aggressive management
56. Pulmonary fungal infections in patients with hematological malignancies - Diagnostic approaches
57. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomography scan and surgery
58. Increasing volume and changing characteristics of invasive pulmonary Aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia
59. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis
60. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening
61. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation
62. Novel triazole antifungal agents
63. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
64. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients
65. Randomized, double-blind study of the safety and antifungal efficacy of ravuconazole relative to fluconazole in esophageal candidiasis
66. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
67. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy
68. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
69. UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis
70. Open, randomized comparison ofvoriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy (OLAT) for primary therapy of invasive aspergillosis (IA)
71. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
72. Lipopeptide inhibitors of fungal glucan synthase
73. Caspofungin:pharmacology, safety and therapeutic potential in superficial and invasive fungal infections
74. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis
75. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis
76. A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients
77. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles
78. Caspofungin vs. Amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: A multicenter, randomized, double-blind study
79. A multicentre, open-label clinical study of FK463 in patients with deep mycoses in Japan
80. Initial experience with FK463 for the treatment of candidemia in cancer patients
81. Rationale for combinations antifungal therapy
82. Antifungal combination therapy
83. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms
84. A comparison of amphotericin B alone and in combination with flucytosine in the treatment of cryptococcal meningitis
85. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
86. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
87. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis
88. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism
89. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as treatment of candidemia in non-neutropneicneutropenic patients
90. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin
91. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans
92. The role of immunoreconstitution in the management of refractory opportunistic fungal infections
93. Survival and prognostic factors ofinvasive aspergillosis after allogeneic bone marrow transplantation
94. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression
95. Cytokines and mycoses
96. Granulocyte transfusions. Time for a second look
97. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
98. Non-myelocytic immune response to invasive aspergillosis following lethal irradiation and hematopoietic stem cell transplantation
99. T cell vaccination in mice with invasive pulmonary aspergillosis